FiercePharma20h
Sanofi API plant hit with FDA warning letter detailing quality, consistency flubs
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...
STAT17h
Sanofi is warned by the FDA over ‘significant’ problems at a key manufacturing plant
The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...
Sanofi says FDA lifted clinical hold on trial for Cialis OTC switch
Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a ...
FiercePharma21h
Sanofi's consumer health arm Opella secures FDA green light to pursue OTC Cialis study
After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...
Sanofi (NASDAQ:SNY) Shares Purchased by Clarius Group LLC
Clarius Group LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 11.9% in the fourth quarter, ...
Sanofi's Opella: FDA Lifts Clinical Hold On OTC Cialis Trial
Sanofi's Consumer Healthcare division, Opella, announced that the U.S. Food and Drug Administration has lifted a clinical hold on its ...
Sanofi’s Growth Prospects and Undervalued Position Highlighted by Analyst Graham Parry
Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...
Sanofi: Underappreciated Powerhouse Primed For Long-Term Growth (Rating Upgrade)
Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...